TFAP2A is a sequence-specific DNA-binding transcription factor that recognizes the consensus sequence 5'-GCCNNNGGC-3' and regulates transcription of diverse genes [UniProt]. As a critical regulator of ectodermal development, TFAP2A is essential for neural crest and cranial placode specification during early development 1, and is the only AP-2 protein required for lens vesicle morphogenesis [UniProt]. TFAP2A orchestrates gene regulatory networks controlling kidney tubular architecture by regulating Wnt9b and Alcam expression in collecting ducts 2. Beyond developmental roles, TFAP2A functions as a tumor suppressor: it inhibits hepatic lipogenesis by binding promoters of SREBP1, ACC, and FASN, and suppresses hepatocellular carcinoma progression 3. In renal cell carcinoma, TFAP2A cooperates with EP300 to regulate PD-L1 expression, influencing immune evasion 4. Additionally, TFAP2A participates in vascular smooth muscle cell regulation, with disrupted TFAP2A-mediated ITGA6 transcription contributing to aortic aneurysm pathogenesis 5. Mutations in TFAP2A cause branchiooculofacial syndrome, an autosomal dominant disorder characterized by craniofacial, branchial, and ocular abnormalities 6, reflecting its essential role in facial development 7.